

1.175.219

PATENT SPECIFICATION

NO DRAWINGS

1.175.219



Inventors: IVOR JAMES STEWART BROWN, RICHARD CLARKSON, NEVILLE STANTON CROSSLEY and BERNARD JOSEPH McLOUGHLIN

Date of filing Complete Specification: 29 May, 1968.

Date of Application (No. 28824/67): 22 June, 1967.

Complete Specification Published: 23 Dec., 1969.

Index at acceptance:—C2 U(3, 4A1, 4A2, 4B1, 4C1, 4C2, 4C3, 4C4, 4C5, 4C9, 4D, 4X); A5 B(24Y, 240, 242, 243, 244, 246, 248, 27Y, 272, 38Y, 381, 382, 384, 39X, 79Y); C2 C(3A10E3A4, 3A10E5F1A, 3A10E5F2A, 3A10E5F3A, 3A10E5F3B, 3A12A3, 3A12A4B, 3A12B2, 3A12C3, 3A12C4, 3A13A3A4, 3A13A3B2, 3A13A3F1, 3A14A3C, 3A14A7B, 3A14B2A2, 3A14B7B, 200, 211, 213, 22Y, 22X, 225, 227, 246, 247, 25Y, 253, 28X, 30Y, 32Y, 323, 351, 352, 353, 36Y, 360, 361, 363, 366, 368, 43X, 620, 628, 633, 65X, 650, 652, 658, 662, 682, 79Y, 790, 178—196—274, 181—193—275, 181—270—283, 183—271—286, 184—196—281, LQ, LZ).

International Classification:—C 07 c 169/00, 171/00, 173/00


COMPLETE SPECIFICATION

3-Aminoalkoxycarbonylmethylene Steroid Derivatives

We, IMPERIAL CHEMICAL INDUSTRIES LIMITED of Imperial Chemical House, Millbank, London, S.W.1, a British Company, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

This invention relates to new steroid derivatives and more particularly it relates to 3-substituted steroid derivatives which possess digitalis-like activity.

According to the invention we provide new steroid derivatives of the formula:—



wherein R^1 and R^2 , which may be the same or different, stand for alkyl radicals, or wherein R^1 and R^2 are joined, together with the adjacent nitrogen atom, to form a heterocyclic radical; wherein A stands for a straight- or branched-chain alkylene radical; and wherein



represents a steroid of which X is the carbon atom at position 3, which steroid is an oestrane, androstane, pregnane, cholane, cholestane or spirostane derivative which may optionally bear one or more substituents selected from oxo radicals, hydroxy radicals, acyloxy radicals, glycosyloxy radicals, alkylenedioxy radicals of which the two oxygen atoms may be attached to the same carbon atom or to neighbouring carbon atoms of the steroid, alkyl radicals, alkylene radicals, halogen atoms and carboxy radicals: and wherein the said steroid may optionally be modified in one or more ways selected from the following: one or more olefinic double bonds or, where possible, acetylenic triple bonds may be present; one ring of the steroid may be expanded; one of the carbon atoms of the steroid may be removed; one or more rings of the steroid may be subject to fission; one or more hetero atoms may be present in the steroid; and the configuration at one or more of the asymmetric centres of the steroid may be inverted; and the acid-addition salts thereof.

It is to be understood that when a hydroxy radical and a carboxy radical are both present in the steroid the product may exist as a lactone.

As a suitable value for R^1 or R^2 when it stands for an alkyl radical there may

[Price 4s. 6d.]

BEST AVAILABLE COPY

be mentioned, for example, an alkyl radical of up to 6 carbon atoms, for example the methyl or ethyl radical.

As a suitable value for the heterocyclic radical formed by R¹, R² and the adjacent nitrogen atom there may be mentioned, for example, a 5-, 6- or 7-membered heterocyclic radical, for example the pyrrolidino, piperidino- or morpholino- radical.

As a suitable value for the alkylene radical A there may be mentioned, for example, a straight- or branched-chain alkylene radical of at least 2 and up to 6 carbon atoms, for example the ethylene ($-\text{CH}_2\text{CH}_2-$), propylene ($-\text{CH}_2\text{CH}_2\text{CH}_2-$),

1-methylethylene $\begin{array}{c} \text{CH}_3 \\ | \\ (-\text{CHCH}_2-) \end{array}$ or 2-methylethylene $\begin{array}{c} \text{CH}_3 \\ | \\ (-\text{CH}_2\text{CH}-) \end{array}$ radical.

As a suitable acyloxy radical which may be a substituent in the steroid there may be mentioned, for example, an alkanoyloxy, alkoxycarbonyloxy or aryloxy radical each of up to 10 carbon atoms, for example an acetoxo, ethoxycarbonyloxy or benzoyloxy radical.

As a suitable glycosyloxy radical which may be a substituent in the steroid there may be mentioned, for example, a hexosyloxy radical, for example the β -D-glucopyranosyloxy or tetra-O-acetyl- β -D-glucopyranosyloxy radical.

As a suitable alkylenedioxy radical which may be a substituent in the steroid there may be mentioned, for example, the ethylenedioxy or isopropylidenedioxy radical.

As a suitable alkyl radical which may be a substituent in the steroid there may be mentioned, for example, an alkyl radical of up to 6 carbon atoms, for example the methyl or ethyl radical.

As a suitable alkylene radical which may be a substituent in the steroid there may be mentioned, for example, an alkylene radical of up to 6 carbon atoms, for example the methylene radical.

As a suitable halogen atom which may be a substituent in the steroid there may be mentioned, for example, the fluorine or chlorine atom.

As a suitable example of a steroid derivative wherein one ring of the steroid is expanded there may be mentioned, for example, a D-homo-steroid derivative.

As a suitable example of a steroid derivative wherein one carbon atoms is or are removed from the steroid there may be mentioned, for example, an 18-nor-, 19-nor- or B-nor-steroid derivative.

As a suitable example of a steroid derivative wherein one of the rings of the steroid is subject to fission there may be mentioned, for example, a 13,17-seco-steroid derivative.

As a suitable example of a steroid derivative which contains one or more heteroatoms there may be mentioned, for example, a steroid derivative wherein one or more carbon atoms is or are replaced by one or more hetero atoms, for example an 8-aza-steroid derivative, or a steroid derivative wherein one or more hetero atoms is or are inserted, for example a 12a-oxa-C-homo- or 17a-oxa-D-homo-steroid derivative.

As a suitable example of a steroid derivative wherein the configuration at one or more of the asymmetric centres of the steroid is inverted there may be mentioned, for example, a 10 α -steroid derivative or a 17 β -pregnane derivative.

It is to be understood that in this specification the nomenclature of steroid derivatives used is in accordance with the International Union of Pure and Applied Chemistry 1957 Rules for Nomenclature of Steroids.

As suitable acid-addition salts of the steroid derivatives of the invention there may be mentioned, for example, salts derived from inorganic acids, for example hydrochlorides, hydrobromides, phosphates or sulphates, or salts derived from organic acids, for example acetates, oxalates, citrates, lactates, tartrates, benzoates or salicylates.

Particular new steroid derivatives of the invention are the 3-(2-dimethylamino-ethoxycarbonylmethylene)-derivatives of

5 α -androstan-17 β -ol;

5 α -androstan-17-one;

5 α -oestrane-17-one;

17 β -(β -D-glucopyranosyloxy)-5 α -androstan-

17 β -(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-5 α -androstan-

5 α ,10 α -oestrane-17-one;

D-homo-18-nor-5 α -androstan-13/17a,-cn-17-one;

D-homo-17a-oxa-5 α -androstan-17-one;

17 β -ethoxycarbonyloxy-5 α -androstan-

17 β -benzoyloxy-5 α -androstan-

17,17-ethylenedioxy-5 α -androstan-

- 17 β -hydroxy-5 α -androstane-6-one;
 5 α -androstane-6 β ,17 β -diol;
 2 α -methyl-5 α -androstane-17 β -ol;
 D-homo-17 α -oxa-5 α -androstane;
 5 13,17-seco-5 α -androstane-13 α ,17-diol;
 17 α -methyl-5 α -androstane-17 β -ol;
 17-methylene-5 α -androstane;
 5 α -pregnan-20-one;
 20 β -acetoxy-5 α -pregnane;
 10 21-acetoxy-5 α -pregnan-20-one;
 5 α -pregn-16-en-20-one;
 16 α ,17 α -isopropylidenedioxy-5 α -pregnan-20-one;
 5 α -pregnane-18,20 β -diol;
 20 β -hydroxy-5 α -pregnan-18-oic acid 18 \rightarrow 20 lactone;
 15 17 β -hydroxy-5 α ,17 α -pregnane-21-carboxylic acid 21 \rightarrow 17 lactone;
 5 α ,22 β -spirostane;
 5 α ,22 β -spirostan-12-one;
 5 α ,22 β -spirostan-11-one;
 C-homo-12 α -oxa-5 α ,22 β -spirostan-12-one;
 20 5 α ,22 β -spirostan-12 β -ol;
 4,4-dimethyl-5 α -androstane-17 β -ol;
 5 α -cholestane; and
 methyl 7,12-dioxo-5 β -cholan-24-oate,
 and the acid-addition salts thereof, particularly the oxalate salts thereof.
 25 According to a further feature of the invention we provide a process for the
 manufacture of the steroid derivatives of the invention which comprises the inter-
 action of a 3-oxo-steroid derivative of the formula: —



- wherein X and Y have the meanings stated above, with a phosphonate derivative of
 the formula: —




- wherein R¹, R² and A have the meanings stated above and wherein R³ stands for an
 alkyl radical, in the presence of a strong base, and if an acid addition salt is required,
 reacting the product obtained with an acid.

- As a suitable value for R³ there may be mentioned, for example, an alkyl radical
 of up to 6 carbon atoms, for example the ethyl radical.


- The interaction may be carried out in an inert diluent or solvent, for example
 1,2-dimethoxyethane, diethylene glycol dimethyl ether, tetrahydrofuran, diethyl ether,
 dimethylformamide, dimethylsulphoxide, or an excess of the phosphonate starting
 material, and it may be carried out at ambient temperature, or at an elevated
 temperature, for example at a temperature of between 80° and 100°C. The strong
 base may be, for example, a metal hydride, for example sodium hydride, or a metal
 alkoxide, for example sodium ethoxide or potassium t-butoxide, or it may be a metal
 amide, for example sodamide.

- The phosphonate derivatives used as starting materials in the above process are
 themselves new compounds, and may be prepared as described in co-pending Applica-
 tion No. 25430/69 (Serial No. 1175220).

- According to a further feature of the invention we provide a process for the
 manufacture of the steroid derivatives of the invention which comprises the inter-
 action of a carboxylic acid of the formula: —



- wherein X and Y have the meanings stated above, or of an activated derivative thereof,
 with an alcohol of the formula: —



wherein R¹, R² and A have the meanings stated above, and if an acid addition salt is required, reacting the product obtained with an acid.

A suitable activated derivative of the carboxylic acid is, for example, an acid halide, for example the acid chloride, or the acid anhydride, or a mixed acid anhydride. The activated derivative may optionally be generated *in situ* by, for example, the reaction of the carboxylic acid with a sulphonyl or sulphonyl halide, for example thionyl chloride or benzenesulphonyl chloride.


The interaction may be carried out in an inert diluent or solvent, for example chloroform, and it may be accelerated or completed by the application of heat, for example by heating at the boiling point of the diluent or solvent.

The carboxylic acid used as starting material may be obtained by the hydrolysis of a corresponding ester or of the corresponding nitrile, for example by hydrolysis in an alkaline medium, for example in aqueous potassium hydroxide solution.

The ester used as intermediate may be obtained by the interaction of a 3-oxo-steroid derivative of the formula: —




wherein X and Y have the meanings stated above with a phosphonate derivative of the formula: —



wherein R² has the meaning stated above and wherein R¹ stands for an alkyl radical, for example an ethyl radical, or wherein R¹ stands for a radical of the formula —A—NR³R⁴ wherein A, R³ and R⁴ have the values stated above.

Alternatively, the ester may be obtained by reaction of the said 3-oxo-steroid with an alkoxyacetylene, for example ethoxyacetylene. This interaction may be carried out using the alkoxyacetylene directly in the presence of boron trifluoride etherate as catalyst, in a diluent or solvent, for example methylene chloride, and at ambient temperature or at a lowered temperature, for example between -10 and +10°C., or it may be carried out using a metal derivative of the alkoxyacetylene, for example the lithium derivative or a Grignard derivative, for example the magnesium bromide derivative, in an ethereal solvent, followed by hydrolysis of the alkoxyethynyl derivative thus obtained with aqueous acid, for example with dilute aqueous hydrochloric acid.

The nitrile used as intermediate may be obtained by interaction of a 3-oxo-steroid derivative of the above formula with a phosphonate derivative of the formula: —



wherein R² has the meaning stated above.

As stated above, the new steroid derivatives of the invention possess digitalis-like activity, having positive inotropic, negative chronotropic and negative dromotropic effects on the myocardium. They are useful, therefore, in the clinical management of heart diseases, for example congestive heart failure and atrial arrhythmias. Some of the steroid derivatives also possess anti-inflammatory activity.

According to a further feature of the invention, therefore, we provide pharmaceutical compositions which comprise one or more of the steroid derivatives of the invention, or a salt thereof, in association with a pharmaceutically-acceptable diluent or carrier therefor.

The said pharmaceutical compositions may be in the form of tablets, capsules, aqueous or oily solutions or suspensions, emulsions, sterile injectable aqueous or oily solutions or suspensions, or dispersible powders.

The pharmaceutical compositions of the invention may additionally contain one or more drugs selected from β-adrenergic blocking agents, for example propranolol; other cardiotonic agents, for example digoxin, digitalis preparations, digitoxin and lanatoside C; diuretics, for example furosemide and ethacrynic acid, and thiazide diuretics, for example hydrochlorothiazide and bendroflumazide, and aldosterone antagonists, for example spironolactone; coronary vasodilators, for example nitrite and nitrate esters, for example glyceryl trinitrate, pentaerythritol tetranitrate and

sorbide nitrate, xanthine derivatives, for example theophylline, theobromine and aminophylline, and dipyrindamole; and potassium salts, for example potassium chloride and potassium gluconate.

5 It is expected that the steroid derivatives of the invention will be administered orally or parenterally, initially in the range of 10—50 mg. per patient per day, this dose subsequently being reduced as necessary. 5

The invention is illustrated, but not limited, by the following Examples 1 and 12 to 15 in which the parts are by weight. Examples 2 to 11 and 16 describe the preparations of intermediates.

10

EXAMPLE 1

10

0.30 Part of a 50% dispersion of sodium hydride in oil is added to a solution of 2.2 parts of diethyl 2-dimethylaminoethoxycarbonylmethylphosphonate (prepared as described in Example 16) in 50 parts of 1,2-dimethoxyethane which is maintained in an atmosphere of nitrogen. The mixture is kept at ambient temperature for 10 minutes, and 0.6 part of 17 β -hydroxy-5 α -androstan-3-one is added. The mixture is kept at ambient temperature for 45 minutes, 200 parts of water are added and the mixture is extracted with ether. The ethereal extract is washed with 100 parts of water and dried and to it is added a solution of 0.4 part of oxalic acid in 40 parts of ether. The mixture is filtered and the solid product is washed with ether and crystallised from isopropanol. There is thus obtained 3-(2-dimethylaminoethoxycarbonylmethylene)-5 α -androstan-17 β -ol oxalate hydrate, m.p. 170—172°C.

15

15

20

20


The process described above is repeated using the appropriate steroidal starting material in place of 17 β -hydroxy-5 α -androstan-3-one, and there are thus obtained the compounds described in the following Tables 1 to 3. In one instance (indicated by an asterisk*) the reaction is carried out over 15 minutes instead of over 45 minutes, because a second reactive keto group is present in the molecule; in a second instance (indicated by two asterisks **) the reaction is carried out over 16 hours instead of over 45 minutes; and in a third instance (indicated by three asterisks ***) the reaction is carried out over 16 hours instead of over 45 minutes and in dimethylformamide in place of 1,2-dimethoxyethane. Where no crystallisation solvent is shown the product need not be crystallised.

25

25

30


30

TABLE 1. 5 α -ANDROSTANE DERIVATIVES

Substituent	Salt	m.p. °C.	Crystallisation Solvent	Description of Starting Material (if novel)
17-oxo-	oxalate	200—205	methanol/ isopropanol	
17-oxo-19-nor-	oxalate hemi- hydrate	170—187		
17 β -(β -D-glucopyranosyloxy)- ***	oxalate hemi- hydrate	197—207	methanol/ ethyl acetate	Ex. 2
17 β -(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)-	oxalate sesqui- hydrate	165—177	methanol/ ethyl acetate	Ex. 2
17-oxo-19-nor-10 α -	oxalate hydrate	145—149		
17-oxo-D-homo-18-nor- Δ^{13} (17a)	oxalate	136—142		Ex. 3
17-oxo-D-homo-17a-oxa-	oxalate	170—172	methanol/ ethyl acetate	
17 β -ethoxycarbonyloxy-	oxalate sesqui- hydrate	197—200		
17 β -benzoyloxy-	oxalate hemi- hydrate	202—205		
17,17-ethylenedioxy-	oxalate hemi- hydrate	210—212		Ex. 4
17 β -hydroxy-6-oxo-*	oxalate hydrate	185—192	methanol/ ethyl acetate	
6 β ,17 β -dihydroxy-	oxalate	140—150	methanol/ isopropanol	
17 β -hydroxy-2 α -methyl-**	oxalate hydrate	163—174	methanol/ isopropanol	

TABLE 1 (Cont.)


Substituent	Salt	m.p. °C.	Crystallisation Solvent	Description of Starting Material (if novel)
D-homo-17a-oxa-	oxalate	192—194	methanol/ ethyl acetate	Ex. 5
13 α ,17-dihydroxy- 13,17-seco-	oxalate hemi- hydrate	219—224	methanol/ ethyl acetate	Ex. 6
17 β -hydroxy-17 α -methyl-	oxalate	213—216	methanol/ isopropanol	
17-methylene-	oxalate	210—213	methanol	Ex. 7

TABLE 2. 5 α -PREGNANE DERIVATIVES

Substituent	Salt	m.p. °C.	Crystallisation Solvent	Description of Starting Material (if novel)
20 oxo-	oxalate	195—205		
20 β -acetoxy-	oxalate	180—202		
21-acetoxy-20-oxo-	oxalate hemi- hydrate	186—189	methanol/ ethyl acetate	Ex. 8
20-oxo- Δ^{16} -	oxalate hydrate	185—190		
16 α ,17 α -isopropylidene- dioxy-20-oxo	oxalate hemi- hydrate	180—192		Ex. 9
18,20 β -dihydroxy-	oxalate hydrate	123—128	methanol/ ethyl acetate	Ex. 10

TABLE 2 (Cont.)

Substituent	Salt	m.p. °C.	Crystallisation Solvent	Description of Starting Material (if novel)
20 β -hydroxy-18-oic acid 18 \rightarrow 20-lactone	oxalate	218—219.5 (with decomposition)	methanol/ ethyl acetate	Ex. 11
21-carboxy- 17 β -hydroxy-17 α - 21 \rightarrow 17-lactone	citrate tri- hydrate	120 (with decomposition)		

TABLE 3. 5 α -22 β -SPIROSTANE DERIVATIVES

Substituent	Salt	m.p. °C.
None	oxalate	210—217
12-oxo	oxalate di- hydrate	198—222
12-oxo-C-homo-12 α -oxa-	oxalate hydrate	206—215
11-oxo	oxalate sesqui- hydrate	209—213

EXAMPLE 2

A mixture of 2 parts of 17 β -hydroxy-5 α -androstan-3-one, 4 parts of powdered calcium sulphate, 4 parts of 2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyl bromide, 4 parts of freshly prepared silver oxide and 50 parts of dry, ethanol-free chloroform is stirred at ambient temperature for 17 hours. The suspension is filtered and the filtrate is evaporated to dryness. The residual oil is stirred with ethanol and the mixture is filtered. The solid is crystallised from methanol and there is thus obtained 17 β -(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyloxy)-5 α -androstan-3-one, m.p. 185—186°C.

5 Parts of 10% aqueous sodium hydroxide solution are added to a solution of 1 part of the above compound in 30 parts of hot methanol and the mixture is heated under reflux for 1 hour, cooled and filtered. The solid is crystallised from methanol and there is thus obtained 17 β -(*O*-D-glucopyranosyloxy)-5 α -androstan-3-one, m.p. 251—253°C.

EXAMPLE 3

5 3 β -Hydroxy-D-homo-18-nor-5 α -androst-13(17a)-en-17-one is oxidised with an 8N-solution of chromium trioxide in aqueous 8N-sulphuric acid (Jones' reagent) in acetone by conventional means. There is thus obtained D-homo-18-nor-5 α -androst-13(17a)-ene-3,17-dione, m.p. 199—201°C.

5

EXAMPLE 4

10 The 17,17-ethylenedioxy- derivative of androsterone (3 β -hydroxy-androstan-17-one) is prepared from androsterone, ethylene glycol and toluene-*p*-sulphonic acid by conventional means, and the crude product is oxidised with aqueous 8N-chromium trioxide in pyridine by conventional means. There is thus obtained 17,17-ethylene-dioxy-5 α -androstan-3-one, m.p. 198—199°C.

10

EXAMPLE 5

15 2.0 Parts of 3 β -hydroxy-D-homo-17a-oxa-5 α -androstan-17-one, 500 parts of glacial acetic acid, 3.0 parts of 60% aqueous perchloric acid and 1.8 parts of Adams platinum oxide catalyst are shaken in an atmosphere of hydrogen at atmospheric pressure for 18 hours. The mixture is filtered, water is added to the filtrate and the mixture is extracted three times with 300 parts of ethyl acetate each time. The combined extracts are washed with aqueous sodium bicarbonate solution and then with water, dried over magnesium sulphate and evaporated to dryness. The residue is dissolved in benzene and the solution is chromatographed on 220 parts of magnesium silicate ("Florisil"; "Florisil" is a Registered Trade Mark). The column is eluted with a 5% solution of ethyl acetate in benzene and the eluates are discarded. The column is then eluted with 1,000 parts of a 20% solution of ethyl acetate in benzene and the eluate is evaporated to dryness. The residue is crystallised from petroleum ether (b.p. 40—60°C.) and there is thus obtained 3 β -acetoxy-D-homo-17a-oxa-5 α -androstan-3-one, m.p. 141—144°C.

15

20

25

30 A mixture of 1.08 parts of the above compound, 0.27 part of potassium hydroxide, 54 parts of water and 350 parts of methanol is heated under reflux in an atmosphere of nitrogen for 1 hour. Water is added and the mixture is extracted with ether. The ethereal extract is dried and evaporated to dryness and the residue is crystallised from a mixture of benzene and petroleum ether (b.p. 60—80°C.). There is thus obtained D-homo-17a-oxa-5 α -androstan-3 β -ol, m.p. 182°C.

30

35 The above compound is oxidised with an 8N-solution of chromium trioxide in aqueous 8N-sulphuric acid (Jones' reagent) in acetone by conventional means. The product is crystallised from petroleum ether (b.p. 40—60°C.) and there is thus obtained D-homo-17a-oxa-5 α -androstan-3-one, m.p. 151—153°C.

35

EXAMPLE 6

40 A mixture of 2.9 parts of D-homo-17a-oxa-5 α -androstan-3,17-dione, 300 parts of methanol and 0.6 part of toluene-*p*-sulphonic acid is stirred at ambient temperature for 1 hour. Excess aqueous sodium bicarbonate solution is added and the mixture is extracted with ether. The ethereal extract is dried and evaporated to dryness and the residue is crystallised from ethyl acetate. There is thus obtained 3,3-dimethoxy-D-homo-17a-oxa-5 α -androstan-17-one, m.p. 169—176°C.

40

45 A mixture of 0.1 part of the above compound, 0.1 part of lithium aluminium hydride and 150 parts of dry tetrahydrofuran is stirred at ambient temperature for 75 minutes. 20 Parts of water are gradually added, followed by 50 parts of aqueous 2N-hydrochloric acid, and the mixture is stirred at ambient temperature for 1 hour. The mixture is extracted with ether and the ethereal extract is dried and evaporated to dryness. The residue is stirred with petroleum ether (b.p. 60—80°C.) and the mixture is filtered. The residue is crystallised from a mixture of ethyl acetate and benzene and there is thus obtained 13 α ,17-dihydroxy-13,17-seco-5 α -androstan-3-one, m.p. 145—149°C.

45

50

EXAMPLE 7

55 0.37 Part of an 8N-solution of chromium trioxide in aqueous 8N-sulphuric acid (Jones' reagent) is added to a solution of 1 part of 17-methylene-5 α -androstan-3 β -ol in 100 parts of acetone which is maintained at 0°C. Anhydrous magnesium sulphate and charcoal are added, the mixture is filtered and the filtrate is evaporated to dryness. The residue is crystallised from methanol and there is thus obtained 17-methylene-5 α -androstan-3-one, m.p. 131—133°C.

55

EXAMPLE 8

18.6 Parts of boron trifluoride etherate are added to a mixture of 3.18 parts of 3 β -hydroxy-5 α -pregnan-20-one, 4.65 parts of freshly dried lead tetraacetate, 125 parts of anhydrous benzene and 6 parts of methanol and the mixture is stirred at ambient temperature for 3 days. The mixture is poured into water and the resulting mixture is extracted with benzene. The benzene extract is dried and evaporated to dryness and the residue is crystallised from methanol. There is thus obtained 21-acetoxy-3 β -hydroxy-5 α -pregnan-20-one, m.p. 203—207°C.

The above compound is oxidised with an 8N-solution of chromium trioxide in aqueous 8N-sulphuric acid (Jones' reagent), in acetone by conventional means and the product is crystallised from methanol. There is thus obtained 21-acetoxy-5 α -pregnane-3,20-dione, m.p. 196—199°C.

EXAMPLE 9

A mixture of 2.23 parts of 16 α ,17 α -epoxy-3 β -hydroxy-5 α -pregnan-20-one, 2.11 parts of ethoxycarbonylhydrazine, 79 parts of dioxan and 56 parts of aqueous N-sulphuric acid is stirred at ambient temperature for 17 hours. Water and ethyl acetate are added and the ethyl acetate layer is separated, washed with water, dried and evaporated to dryness. The residue is dissolved in 85 parts of acetone, 2 parts of 70% aqueous perchloric acid are added, and the mixture is stirred at ambient temperature for 2 hours. The mixture is evaporated to dryness, water and chloroform are added and the chloroform layer is separated, dried and evaporated to dryness. The residue is dissolved in benzene and the solution is chromatographed on a column of 100 parts of magnesium silicate ("Florisil"; "Florisil" is a Registered Trade Mark). The column is eluted with a 15% solution of ethyl acetate in hexane. The eluate is evaporated to dryness and the residue is crystallised from ether. There is thus obtained 3 β -hydroxy-16 α ,17 α -isopropylidenedioxy-5 α -pregnan-20-one, m.p. 194—195°C.

The above compound is oxidised with an 8N-solution of chromium trioxide in aqueous 8N-sulphuric acid (Jones' reagent) in acetone in the presence of magnesium sulphate by conventional means. The product is crystallised from petroleum ether (b.p. 60—80°C.) and there is thus obtained 16 α ,17 α -isopropylidenedioxy-5 α -pregnane-3,20-dione, m.p. 183—184°C.

EXAMPLE 10

0.5 Part of ethylene glycol and 0.1 part of toluene *p*-sulphonic acid are added to a solution of 1 part of 20 β -hydroxy-3-oxo-5 α -pregnan-18-oic acid 18 \rightarrow 20 lactone in 50 parts of dry benzene and the mixture is heated under reflux in an apparatus containing a Dean and Stark water separator for 6 hours. The mixture is cooled, washed twice with 30 parts of saturated aqueous sodium bicarbonate solution each time, dried over anhydrous potassium carbonate and evaporated to dryness under reduced pressure. The residue is crystallised from a mixture of benzene and petroleum ether (b.p. 80—100°C.) and there is thus obtained 3,3-ethylenedioxy-20 β -hydroxy-5 α -pregnan-18-oic acid 18 \rightarrow 20 lactone, m.p. 227—229°C.

2 Parts of lithium aluminium hydride are added to a solution of 3.5 parts of the above product in 100 parts of dry tetrahydrofuran and the mixture is stirred and heated under reflux for one hour. The mixture is stirred and cooled in an ice-bath and water is carefully added dropwise in order to destroy the excess lithium aluminium hydride. The mixture is poured into 100 parts of aqueous 2N-sulphuric acid and the resulting mixture is extracted three times with 50 parts of ether each time. The combined ethereal extracts are washed with 30 parts of water, dried over anhydrous potassium carbonate and evaporated to dryness. The residue is crystallised from aqueous methanol and there is thus obtained 3,3-ethylenedioxy-5 α -pregnane-18,20 β -diol, m.p. 211—212°C.

0.1 Part of aqueous 11N-hydrochloric acid is added to a stirred solution of 2.6 parts of the above product in 100 parts of methanol. The mixture is stirred at ambient temperature for 2 hours, and a further 0.1 part of aqueous 11N-hydrochloric acid is then added. The mixture is stirred at ambient temperature for 2 hours and yet a further 0.1 part of aqueous 11N-hydrochloric acid is added. The mixture is stirred at ambient temperature for 2 hours, 400 parts of water are added and the mixture is extracted three times with 100 parts of chloroform each time. The combined chloroform extracts are washed successively with 50 parts of saturated aqueous sodium bicarbonate solution, 50 parts of brine and 50 parts of brine, and are then dried and evaporated to dryness under reduced pressure. The residue is crystallised from aqueous methanol and there is thus obtained 18,20 β -dihydroxy-5 α -pregnan-3-one, m.p. 219—221°C.

EXAMPLE 11

A solution of 0.87 part of 3 β -hydroxy-5 α -androstan-17-one in 10 parts tetrahydrofuran is added to a solution of 3-(2-tetrahydropyranyloxy)prop-1-ynyl magnesium bromide (prepared from 3.95 parts of 2-tetrahydropyranyl propargyl ether and 9.6 parts of a 2.5M solution of methylmagnesium bromide in tetrahydrofuran) in 50 parts of tetrahydrofuran. The mixture is heated under reflux for 20 hours, 10% aqueous ammonium chloride solution and ether are added, and the ethereal layer is separated, washed with water, dried and evaporated to dryness. The residue is dissolved in benzene and the solution is chromatographed on a column of 20 parts of magnesium silicate ("Florisol"; "Florisol" is a Registered Trade Mark). The column is eluted with a 3% solution of ethyl acetate in petroleum ether (b.p. 60–80°C.) and the eluate is discarded. The column is then eluted with a 50% solution of ethyl acetate in petroleum ether (b.p. 60–80°C.) and the eluate is evaporated to dryness. The residue is crystallised from petroleum ether (b.p. 40–60°C.) and there is thus obtained 17 α -[3-(2-tetrahydropyranyloxy)prop-1-ynyl]-5 α -androstan-3 β ,17 β -diol, m.p. 75–78°C. (with decomposition).

A solution of 2.15 parts of the above compound in 100 parts of ethanol is shaken with 0.05 part of Adams platinum oxide catalyst in an atmosphere of hydrogen until uptake of hydrogen ceases. The mixture is filtered and the filtrate is evaporated to dryness. The residue is crystallised from aqueous methanol and there is thus obtained 17 α -[3-(2-tetrahydropyranyloxy)propyl]-5 α -androstan-3 β ,17 β -diol, m.p. 135–139°C.

A solution of 0.432 part of the above compound in a mixture of 23 parts of chloroform and 10 parts of aqueous N-hydrochloric acid is stirred and heated under reflux in an atmosphere of nitrogen for 18 hours. The mixture is evaporated to dryness, 10 parts of water are added and the mixture is stirred. The water is decanted off, the residue is stirred with methanol and the mixture is filtered. There is thus obtained crude 17 α -(3-hydroxypropyl)-5 α -androstan-3 β ,17 β -diol which is used without further purification.

1.1 Parts of an 8N-solution of chromium trioxide in aqueous 8N-sulphuric acid are added to a solution of 0.35 part of the above compound in 50 parts of acetone and the mixture is kept for 15 minutes at 0°C. and then for 2 hours at ambient temperature. Isopropanol is added to destroy the excess oxidising agent, water is then added and the pH of the solution is adjusted to 1 with concentrated aqueous hydrochloric acid. The mixture is kept at ambient temperature for 10 minutes and is then extracted with chloroform. The chloroform extract is dried and evaporated to dryness and the residue is crystallised from aqueous methanol. There is thus obtained 21-carboxy-17 β -hydroxy-5 α ,17 α -pregnan-3-one 21 \rightarrow 17 lactone, m.p. 173–176°C.

EXAMPLE 12

The process described in Example 1 is repeated except that 0.5 part of 5 α -cholestan-3-one is used as starting material in place of the 0.6 part of 17 β -hydroxy-5 α -androstan-3-one. The product is crystallised from a mixture of methanol and ethyl acetate and there is thus obtained 3-(2-dimethylaminoethoxycarbonylmethylene)-5 α -cholestan-3-one oxalate, m.p. 200–210°C.

EXAMPLE 13

The process described in Example 1 is repeated except that methyl 7,12-dioxo-5 β -cholan-24-oate is used as starting material in place of 17 β -hydroxy-5 α -androstan-3-one. The product is crystallised from a mixture of methanol and ethyl acetate and there is thus obtained methyl 3-(2-dimethylaminoethoxycarbonylmethylene)-7,12-dioxo-5 β -cholan-24-oate oxalate trihydrate, m.p. 75–80°C.

EXAMPLE 14

0.05 Part of triethylamine is added to a solution of 0.18 part of 3-carboxymethylene-4,4-dimethyl-5 α -androstan-17 β -ol in 7.5 parts of dry ethanol-free chloroform, and the mixture is cooled to –10°C. in an atmosphere of nitrogen. 0.088 Part of benzenesulphonylchloride is added and the mixture is stirred at –10°C. for 20 minutes. 0.089 Part of 2-dimethylaminoethanol is then added and the mixture is stirred at –10°C. for 1 hour and is then heated under reflux for 18 hours. The mixture is washed with aqueous sodium carbonate solution, dried over potassium carbonate and evaporated to dryness. The residue is dissolved in ether and a solution of oxalic acid in ether is added. The mixture is filtered and the solid product is crystallised from a mixture of ethyl acetate and methanol. There is thus obtained 3-(2-

dimethylaminoethoxycarbonylmethylene-,4,4-dimethyl-5 α -androstan-17 β -ol, m.p. 221—222°C.

The 3-carboxymethylene-4,4-dimethyl-5 α -androstan-17 β -ol used as starting material may be obtained as follows:—

A solution of 0.36 part of 17 β -hydroxy-4,4-dimethyl-5 α -androstan-3-one in 25 parts of methylene chloride is cooled to between 0 and -10°C. and 0.25 part of boron trifluoride etherate and 0.175 part of ethoxyacetylene are added. The mixture is kept at ambient temperature for 18 hours, cooled to -10°C. and further portions of 0.025 part of boron trifluoride etherate and 0.175 part of ethoxyacetylene are added. The mixture is stirred at 0°C. for one hour and then at ambient temperature for 2 hours. The mixture is washed with aqueous sodium carbonate solution, dried over potassium carbonate and evaporated to dryness. The residue is dissolved in 10 parts of benzene and the solution is chromatographed on magnesium silicate ("Florisil"; "Florisil" is a Registered Trade Mark), using benzene as eluant. The eluate is evaporated to dryness and the residue is crystallised from petroleum ether (b.p. 60—80°C.). There is thus obtained 17 β -acetoxy-3-ethoxycarbonylmethylene-4,4-dimethyl-5 α -androstan-17 β -ol, m.p. 167—169°C.

3 Parts of 5% aqueous potassium hydroxide solution are added to a solution of 0.187 part of the above compound in 20 parts of methanol and the mixture is heated under reflux for 18 hours in an atmosphere of nitrogen. The solution is cooled, water is added and the mixture is washed with ether. The aqueous phase is acidified and the mixture is extracted with ether. The ethereal solution is dried and evaporated to dryness and the residue is crystallised from aqueous methanol. There is thus obtained 3-carboxymethylene-4,4-dimethyl-5 α -androstan-17 β -ol, m.p. 253—255°C.

EXAMPLE 15


0.518 Part of 3-(2-dimethylaminoethoxycarbonylmethylene-,5 α ,22 β -spirostan-12-one is added to a solution of 1 part of lithium tri-*t*-butoxy-aluminium hydride in 10 parts of tetrahydrofuran and the mixture is stirred at ambient temperature for 2 hours. The product is isolated by conventional means and dissolved in ether, and the ethereal solution is treated with a solution of 0.2 part of oxalic acid in 25 parts of ether. The mixture is filtered and there is thus obtained a solid residue 3-(2-dimethylaminoethoxycarbonylmethylene-,5 α ,22 β -spirostan-12 β -ol oxalate, m.p. 208—210°C.

EXAMPLE 16

A solution of 22.4 parts of triethyl phosphonoacetate, 9.79 parts of *N,N*-dimethylaminoethanol and 0.24 part of a 50% dispersion of sodium hydride in oil in 100 parts of cyclohexane is slowly distilled through an efficient fractionation column under an atmosphere of nitrogen. When the column-head temperature has risen to 80°C. (after about 1½ hours), 0.98 part of *N,N*-dimethylaminoethanol and 0.24 part of a 50% dispersion of sodium hydride in oil are added to the reaction mixture. This causes the column-head temperature to fall as further quantities of the cyclohexane/ethanol azeotrope distil over. When the column-head temperature has again risen to 80°C. (after about 2 hours), still further amounts of *N,N*-dimethylaminoethanol and a 50% dispersion of sodium hydride in oil are added, and the distillation is continued for a further 30 minutes. Throughout the reaction cyclohexane is added to the reaction mixture to keep the volume of the reaction mixture constant. The solvent is evaporated from the residue in the distillation vessel and the residue is distilled. There is thus obtained diethyl 2-dimethylaminoethoxycarbonylmethylphosphonate, b.p. 119—123°C./0.35 mm.

WHAT WE CLAIM IS:—

1. Steroid derivatives of the formula:—



wherein R¹ and R², which may be the same or different, stand for alkyl radicals, or wherein R¹ and R² are joined, together with the adjacent nitrogen atom, to form a heterocyclic radical; wherein A stands for a straight- or branched-chain alkylene radical; and wherein:



5 represents a steroid of which X is the carbon atom at position 3, which steroid is an
oestrane, androstane, pregnane, cholane, cholestane or spirostane derivative which
may optionally bear one or more substituents selected from oxo radicals, hydroxy
radicals, acyloxy radicals, glycosyloxy radicals, alkylenedioxy radicals of which the
two oxygen atoms may be attached to the same carbon atom or to neighbouring carbon
atoms of the steroid, alkyl radicals, alkylene radicals, halogen atoms and carboxy
radicals; and wherein the said steroid may optionally be modified in one or more
ways selected from the following: one or more olefinic double bonds or, where
possible, acetylenic triple bonds may be present; one ring of the steroid may be
expanded; one of the carbon atoms of the steroid may be removed; one ring of the
steroid may be subject to fission; one or more hetero atoms may be present in the
steroid; and the configuration at one or more of the asymmetric centres of the steroid
may be inverted; and the acid-addition salts thereof.

15 2. Steroid derivatives as claimed in claim 1 wherein R¹ and R², which may be
the same or different, stand for alkyl radicals of up to 6 carbon atoms, or wherein
R¹ and R² are joined, together with the adjacent nitrogen atom, to form a 5-, 6- or
7-membered heterocyclic radical; wherein A stands for a straight- or branched-chain
alkylene radical of at least 2 and up to 6 carbon atoms; and wherein



20 represents a steroid of which X is the carbon atom at position 3, which steroid is an
oestrane, androstane, pregnane, cholane, cholestane or spirostane derivative which
may optionally bear one or more substituents selected from oxo radicals; hydroxy
radicals; alkanoyloxy, alkoxycarbonyloxy and aryloxy radicals each of up to 10
carbon atoms; hexosyloxy radicals; alkylenedioxy radicals of up to 6 carbon atoms
of which the two oxygen atoms may be attached to the same carbon or to neighbouring
carbon atoms of the steroid; alkyl radicals of up to 6 carbon atoms; alkylene radicals
of up to 6 carbon atoms; halogen atoms and carboxy radicals; and wherein the said
steroid may optionally be modified as stated in claim 1; and the acid addition salts
thereof.

25 3. Steroid derivatives as claimed in claim 2 wherein R¹ and R², which may be
the same or different, stand for methyl or ethyl radicals or wherein R¹ and R² are
joined, together with the adjacent nitrogen atom, to form a pyrrolidino, piperidino-
or morpholino- radical; where A stands for the ethylene, propylene, 1-methylethylene
or 2-methylethylene radical; and wherein

30

35




40 represents a steroid of which X is the carbon atom at position 3, which steroid is an
oestrane, androstane, pregnane, cholane, cholestane or spirostane derivative which may
optionally bear one or more substituents selected from oxo, hydroxy, acetoxy, ethoxy-
carbonyloxy, benzoyloxy, β -D-glucopyranosyloxy, tetra-O-acetyl- β -D-glucopyrano-
syloxy, ethylenedioxy, isopropylidenedioxy, methyl, ethyl, methylene and carboxy
radicals, and fluorine and chlorine atoms; and wherein the said steroid may optionally
contain one or more olefinic double bonds and/or, where possible, acetylenic triple
bonds, and which steroid may optionally be a D-homo-steroid derivative, an 18-nor-,
19-nor- or B-nor-steroid derivative, a 13,17-seco-steroid derivative, an 8-aza-steroid
derivative, a 12 α -oxa-C-homo- or 17 α -oxa-D-homo-steroid derivative, a 10 α -steroid
derivative or a 17 α -pregnane derivative; and the hydrochlorides, hydrobromides,
phosphates, sulphates, acetates, oxalates, citrates, lactates, tartrates, benzoates or
salicylates thereof.

45

4. The 3-(2-dimethylaminoethoxycarbonylmethylene)-derivatives of
 5α -androstane-17 β -ol;
 5α -androstane-17-one;
 5α -oestrane-17-one;
 5 17 β -(β -D-glucopyranosyloxy)- 5α -androstane;
 17 β -(2,3,4,6-tetra-O-acetyl- β -D-glucopyranosyloxy)- 5α -androstane;
 5α ,10 α -oestrane-17-one;
 D-homo-13-nor- 5α -androst-13(17a),-en-17-one;
 D-homo-17a-oxa- 5α -androstane-17-one;
 10 17 β -ethoxycarbonyloxy- 5α -androstane;
 17 β -benzoyloxy- 5α -androstane;
 17,17-ethylenedioxy- 5α -androstane;
 17 β -hydroxy- 5α -androstane-6-one;
 5α -androstane-6 β ,17 β -diol;
 15 2 α -methyl- 5α -androstane-17 β -ol;
 D-homo-17a-oxa- 5α -androstane;
 13,17-seco- 5α -androstane-13 α ,17-diol;
 17 α -methyl- 5α -androstane-17 β -ol;
 17-methylene- 5α -androstane;
 20 5α -pregnan-20-one;
 20 β -acetoxy- 5α -pregnane;
 21-acetoxy- 5α -pregnan-20-one;
 5α -pregn-16-en-20-one;
 16 α ,17 α -isopropylidenedioxy- 5α -pregnan-20-one;
 25 5α -pregnane-18,20 β -diol;
 20 β -hydroxy- 5α -pregnan-18-oic acid 18 \rightarrow 20 lactone;
 17 β -hydroxy- 5α ,17 α -pregnane-21-carboxylic acid 21 \rightarrow 17 lactone;
 5α ,22 β -spirostane;
 5α ,22 β -spirostan-12-one;
 5α ,22 β -spirostan-11-one;
 30 C-homo-12a-oxa- 5α ,22 β -spirostan-12-one;
 5α ,22 β -spirostan-12 β -ol;
 4,4-dimethyl- 5α -androstane-17 β -ol;
 5α -cholestane; and
 35 methyl 7,12-dioxo- 5β -cholan-24-oate,
 and the acid addition salts thereof.
 5. Acid-addition salts as claimed in claim 4 which are oxalates.
 6. A process for the manufacture of the steroid derivatives, claimed in any of
 claims 1 to 5, which comprises the interaction of a 3-oxo-steroid derivative of the
 40 formula: —




wherein X and Y have the meanings stated in claim 1 with a phosphonate derivative of the formula: —



- 45 wherein R^1 , R^2 and A have the meanings stated in claim 1 and wherein R^2 stands for an alkyl radical, in the presence of a strong base, and if an acid addition salt is required, reacting the product obtained with an acid.
 7. A process as claimed in claim 6 wherein R^2 stands for the ethyl radical.
 8. A process as claimed in claim 6 or 7 which is carried out in a diluent or solvent
 50 selected from 1,2-dimethoxyethane, diethyleneglycol dimethyl ether, tetrahydrofuran, diethyl ether, dimethylformamide, dimethylsulphoxide and an excess of the phosphonate starting material.
 9. A process as claimed in any of claims 6, 7 and 8 wherein the strong base is a
 metal hydride, a metal alkoxide or a metal amide.
 55 10. A process as described in claim 6 which comprises the interaction of a 3-oxo-steroid derivative of the formula




wherein X and Y have the meanings stated in claim 1, with a phosphonate derivative of the formula



5 in the presence of sodium hydride, in dimethoxyethane as solvent, and at ambient temperature. 5

11. A process for the manufacture of the steroid derivatives, claimed in any of claims 1 to 5, which comprises the interaction of a carboxylic acid of the formula:



10 wherein X and Y have the meanings stated in claim 1, or of an activated derivative thereof, with an alcohol of the formula:— 10



wherein A, R¹ and R² have the meanings stated in claim 1, and if an acid addition salt is required, reacting the product obtained with an acid.

15 12. A process as claimed in claim 11 wherein the activated derivative of the carboxylic acid is an acid halide, an acid anhydride or a mixed acid anhydride. 15

13. A process as claimed in claim 11 or 12 which is carried out in an inert diluent or solvent, and which is accelerated or completed by the application of heat.

20 14. Pharmaceutical compositions which comprise one or more of the steroid derivatives, claimed in any of claims 1 to 5, or an acid-addition salt thereof, in association with a pharmaceutically-acceptable diluent or carrier therefor. 20

15. Pharmaceutical compositions as claimed in claim 14 which are in the form of tablets, capsules, aqueous or oily solutions or suspensions, emulsions, sterile injectable aqueous or oily solutions or suspensions, or dispersible powders.

25 16. Pharmaceutical compositions as claimed in claim 14 or 15 which additionally contain one or more drugs selected from β -adrenergic blocking agents, other cardiotonic agents, diuretics, coronary vasodilators and potassium salts. 25

30 17. Steroid derivatives claimed in any one of claims 1 to 5, and processes for their manufacture, claimed in any of claims 6 to 13, as hereinbefore particularly described in Examples 1 and 12 to 15. 30

B. F. DREW,
Agent for the Applicants.

This Page Blank (uspto)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☒ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)